Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2016, Article ID 5785786, 7 pages
http://dx.doi.org/10.1155/2016/5785786
Review Article

Cancer Stem Cells and Radioresistance: Rho/ROCK Pathway Plea Attention

1St. John’s Medical College Hospital, Bangalore 560034, India
2National Centre for Biological Sciences, Bangalore 560065, India

Received 12 May 2016; Accepted 20 July 2016

Academic Editor: Zhi Sheng

Copyright © 2016 Annapurna Pranatharthi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. M. Richards, “Deoxyribose nucleic acid values in tumour cells with reference to the stem-cell theory of tumour growth,” Nature, vol. 175, no. 4449, pp. 259–261, 1955. View at Publisher · View at Google Scholar · View at Scopus
  2. M. F. Clarke, J. E. Dick, P. B. Dirks et al., “Cancer stem cells—perspectives on current status and future directions: AACR workshop on cancer stem cells,” Cancer Research, vol. 66, no. 19, pp. 9339–9344, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. M. F. Clarke and M. Fuller, “Stem cells and cancer: two faces of eve,” Cell, vol. 124, no. 6, pp. 1111–1115, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Bonnet and J. E. Dick, “Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell,” Nature Medicine, vol. 3, no. 7, pp. 730–737, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. S. K. Singh, I. D. Clarke, T. Hide, and P. B. Dirks, “Cancer stem cells in nervous system tumors,” Oncogene, vol. 23, no. 43, pp. 7267–7273, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez, S. J. Morrison, and M. F. Clarke, “Prospective identification of tumorigenic breast cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 7, pp. 3983–3988, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. C. A. O'Brien, A. Pollett, S. Gallinger, and J. E. Dick, “A human colon cancer cell capable of initiating tumour growth in immunodeficient mice,” Nature, vol. 445, no. 7123, pp. 106–110, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Zhang, C. Balch, M. W. Chan et al., “Identification and characterization of ovarian cancer-initiating cells from primary human tumors,” Cancer Research, vol. 68, no. 11, pp. 4311–4320, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Li, D. G. Heidt, P. Dalerba et al., “Identification of pancreatic cancer stem cells,” Cancer Research, vol. 67, no. 3, pp. 1030–1037, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. N. J. Maitland and A. T. Collins, “Prostate cancer stem cells: a new target for therapy,” Journal of Clinical Oncology, vol. 26, no. 17, pp. 2862–2870, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Asfaha, Y. Hayakawa, A. Muley et al., “Krt19+/Lgr5 cells are radioresistant cancer-initiating stem cells in the colon and intestine,” Cell Stem Cell, vol. 16, no. 6, pp. 627–638, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Bao, Q. Wu, R. E. McLendon et al., “Glioma stem cells promote radioresistance by preferential activation of the DNA damage response,” Nature, vol. 444, no. 7120, pp. 756–760, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. X. Gao, J. T. McDonald, L. Hlatky, and H. Enderling, “Acute and fractionated irradiation differentially modulate glioma stem cell division kinetics,” Cancer Research, vol. 73, no. 5, pp. 1481–1490, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. T. M. Phillips, W. H. McBride, and F. Pajonk, “The response of CD24-/low/CD44+ breast cancer-initiating cells to radiation,” Journal of the National Cancer Institute, vol. 98, no. 24, pp. 1777–1785, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Beier, P. Hau, M. Proescholdt et al., “CD133+ and CD133 glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles,” Cancer Research, vol. 67, no. 9, pp. 4010–4015, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Wang, P. Ø. Sakariassen, O. Tsinkalovsky et al., “CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells,” International Journal of Cancer, vol. 122, no. 4, pp. 761–768, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Gomez-Casal, C. Bhattacharya, N. Ganesh et al., “Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes,” Molecular Cancer, vol. 12, no. 1, article 94, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Y. W. Bourguignon, Z. Hongbo, L. Shao, and Y. W. Chen, “CD44 interaction with tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration,” The Journal of Biological Chemistry, vol. 275, no. 3, pp. 1829–1838, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. J. López, A. Poitevin, V. Mendoza-Martínez, C. Pérez-Plasencia, and A. García-Carrancá, “Cancer-initiating cells derived from established cervical cell lines exhibit stem-cell markers and increased radioresistance,” BMC Cancer, vol. 12, article 48, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Shweiki, A. Itin, G. Neufeld, H. Gitay-Goren, and E. Keshet, “Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis,” The Journal of Clinical Investigation, vol. 91, no. 5, pp. 2235–2243, 1993. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Damert, E. Ikeda, and W. Risau, “Activator-protein-1 binding potentiates the hypoxia-inducible factor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells,” Biochemical Journal, vol. 327, no. 2, pp. 419–423, 1997. View at Publisher · View at Google Scholar · View at Scopus
  22. P. J. Kallio, K. Okamoto, S. O'Brien et al., “Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1α,” The EMBO Journal, vol. 17, no. 22, pp. 6573–6586, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. J. M. Heddleston, Z. Li, J. D. Lathia, S. Bao, A. B. Hjelmeland, and J. N. Rich, “Hypoxia inducible factors in cancer stem cells,” British Journal of Cancer, vol. 102, no. 5, pp. 789–795, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Diehn, R. W. Cho, N. A. Lobo et al., “Association of reactive oxygen species levels and radioresistance in cancer stem cells,” Nature, vol. 458, no. 7239, pp. 780–783, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Cheng, Q. Wu, Z. Huang et al., “L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1,” The EMBO Journal, vol. 30, no. 5, pp. 800–813, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. W.-J. Wang, S.-P. Wu, J.-B. Liu et al., “MYC regulation of CHK1 and CHK2 promotes radioresistance in a stem cell-like population of nasopharyngeal carcinoma cells,” Cancer Research, vol. 73, no. 3, pp. 1219–1231, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. N. E. Bhola, V. M. Jansen, J. P. Koch et al., “Treatment of triple-negative breast cancer with TORC1/2 inhibitors sustains a drug-resistant and notch-dependent cancer stem cell population,” Cancer Research, vol. 76, no. 2, pp. 440–452, 2016. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Levens and P. D. Aplan, “Notching Up MYC gives a LIC,” Cell Stem Cell, vol. 13, no. 1, pp. 8–9, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. M. K. Asiedu, J. N. Ingle, M. D. Behrens, D. C. Radisky, and K. L. Knutson, “TGFβ/TNFα-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype,” Cancer Research, vol. 71, no. 13, pp. 4707–4719, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Shinojima, A. Hossain, T. Takezaki et al., “TGF-β mediates homing of bone marrow-derived human mesenchymal stem cells to glioma stem cells,” Cancer Research, vol. 73, no. 7, pp. 2333–2344, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Barber, T. Zhang, L. R. DeMars, J. Conejo-Garcia, K. F. Roby, and C. L. Sentman, “Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer,” Cancer Research, vol. 67, no. 10, pp. 5003–5008, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. V. Catalano, M. Dentice, R. Ambrosio et al., “Activated thyroid hormone promotes differentiation and chemotherapeutic sensitization of colorectal cancer stem cells by regulating Wnt and BMP4 signaling,” Cancer Research, vol. 76, no. 5, pp. 1237–1244, 2016. View at Publisher · View at Google Scholar
  33. N. Takebe, L. Miele, P. J. Harris et al., “Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update,” Nature Reviews Clinical Oncology, vol. 12, no. 8, pp. 445–464, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. I. Ader, C. Delmas, J. Bonnet et al., “Inhibition of Rho pathways induces radiosensitization and oxygenation in human glioblastoma xenografts,” Oncogene, vol. 22, no. 55, pp. 8861–8869, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. A. R. Kidd III, J. L. Snider, T. D. Martin, S. F. Graboski, C. J. Der, and A. D. Cox, “Ras-related small GTPases RalA and RalB regulate cellular survival after ionizing radiation,” International Journal of Radiation Oncology Biology Physics, vol. 78, no. 1, pp. 205–212, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Ridley, “Molecular switches in metastasis,” Nature, vol. 406, no. 6795, pp. 466–467, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. A. L. Bishop and A. Hall, “Rho GTPases and their effector proteins,” Biochemical Journal, vol. 348, no. 2, pp. 241–255, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Van Aelst and C. D'Souza-Schorey, “Rho GTPases and signaling networks,” Genes and Development, vol. 11, no. 18, pp. 2295–2322, 1997. View at Publisher · View at Google Scholar · View at Scopus
  39. N. K. Hussain, S. Jenna, M. Glogauer et al., “Endocytic protein intersectin-l regulates actin assembly via Cdc42 and N-WASP,” Nature Cell Biology, vol. 3, no. 10, pp. 927–932, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Schmidt and A. Hall, “The Rho exchange factor Net1 is regulated by nuclear sequestration,” The Journal of Biological Chemistry, vol. 277, no. 17, pp. 14581–14588, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. D. K. Worthylake, K. L. Rossman, and J. Sondek, “Crystal structure of Rac1 in complex with the guanine nucleotide exchange region of Tiam1,” Nature, vol. 408, no. 6813, pp. 682–688, 2000. View at Publisher · View at Google Scholar · View at Scopus
  42. B. Olofsson, “Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling,” Cellular Signalling, vol. 11, no. 8, pp. 545–554, 1999. View at Publisher · View at Google Scholar · View at Scopus
  43. M. A. Del Pozo, W. B. Kiosses, N. B. Alderson, N. Meller, K. M. Hahn, and M. A. Schwartz, “Integrins regulate GTP-Rac localized effector interactions through dissociation of Rho-GDI,” Nature Cell Biology, vol. 4, no. 3, pp. 232–239, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Srivastava, B. Ramdass, S. Nagarajan, M. Rehman, G. Mukherjee, and S. Krishna, “Notch1 regulates the functional contribution of RhoC to cervical carcinoma progression,” British Journal of Cancer, vol. 102, no. 1, pp. 196–205, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. F. M. Vega and A. J. Ridley, “Rho GTPases in cancer cell biology,” FEBS Letters, vol. 582, no. 14, pp. 2093–2101, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. C. Danussi, U. D. Akavia, F. Niola et al., “RHPN2 drives mesenchymal transformation in malignant glioma by triggering RhoA activation,” Cancer Research, vol. 73, no. 16, pp. 5140–5150, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. L.-H. Hang, D.-H. Shao, Z. Chen, and W.-J. Sun, “Spinal RhoA/Rho kinase signalling pathway may participate in the development of bone cancer pain,” Basic and Clinical Pharmacology and Toxicology, vol. 113, no. 2, pp. 87–91, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. W. Chen, N. B. Delongchamps, K. Mao et al., “High RhoA expression at the tumor front in clinically localized prostate cancer and association with poor tumor differentiation,” Oncology Letters, vol. 11, no. 2, pp. 1375–1381, 2016. View at Publisher · View at Google Scholar · View at Scopus
  49. J.-T. Duan, X.-M. Wang, S.-Q. Zhang, and G.-J. Zhao, “Effect of RhoA gene silencing on proliferation and migration of gastric MGC-803 cells,” International Journal of Clinical and Experimental Medicine, vol. 8, no. 8, pp. 14410–14415, 2015. View at Google Scholar · View at Scopus
  50. D. Jeong, S. Park, H. Kim et al., “RhoA is associated with invasion and poor prognosis in colorectal cancer,” International Journal of Oncology, vol. 48, no. 2, pp. 714–722, 2016. View at Publisher · View at Google Scholar · View at Scopus
  51. N. McLaughlin, B. Annabi, M. Bouzeghrane et al., “The Survivin-mediated radioresistant phenotype of glioblastomas is regulated by RhoA and inhibited by the green tea polyphenol (−)-epigallocatechin-3-gallate,” Brain Research, vol. 1071, no. 1, pp. 1–9, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. A. D. Dubash, C. Guilluy, M. C. Srougi, E. Boulter, K. Burridge, and R. García-Mata, “The small GTPase RhoA localizes to the nucleus and is activated by Net1 and DNA damage signals,” PLoS ONE, vol. 6, no. 2, Article ID e17380, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Huang and G. C. Prendergast, “RhoB in cancer suppression,” Histology and Histopathology, vol. 21, no. 2, pp. 213–218, 2006. View at Google Scholar · View at Scopus
  54. I. Ader, C. Toulas, F. Dalenc et al., “RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death,” Oncogene, vol. 21, no. 39, pp. 5998–6006, 2002. View at Publisher · View at Google Scholar · View at Scopus
  55. E. A. Clark, T. R. Golub, E. S. Lander, and R. O. Hynes, “Genomic analysis of metastasis reveals an essential role for RhoC,” Nature, vol. 406, no. 6795, pp. 532–535, 2000. View at Publisher · View at Google Scholar · View at Scopus
  56. X. He, Y. Qian, H. Cai, S. Yang, J. Cai, and Z. Wang, “Rhoc is essential in TGF-β1 induced epithelial-mesenchymal transition in cervical cancer cells,” Oncology Letters, vol. 10, no. 2, pp. 985–989, 2015. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Islam, S. Sharma, and T. N. Teknos, “RhoC regulates cancer stem cells in head and neck squamous cell carcinoma by overexpressing IL-6 and phosphorylation of STAT3,” PLoS ONE, vol. 9, no. 2, article e88527, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. N. Reymond, J. H. Im, R. Garg et al., “RhoC and ROCKs regulate cancer cell interactions with endothelial cells,” Molecular Oncology, vol. 9, no. 6, pp. 1043–1055, 2015. View at Publisher · View at Google Scholar · View at Scopus
  59. D. T. Rosenthal, J. Zhang, L. Bao et al., “RhoC impacts the metastatic potential and abundance of breast cancer stem cells,” PLoS ONE, vol. 7, no. 7, Article ID e40979, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Xie, M. Zhu, G. Lv et al., “Overexpression of ras homologous C (RhoC) induces malignant transformation of hepatocytes in vitro and in nude mouse xenografts,” PLoS ONE, vol. 8, no. 1, Article ID e54493, 2013. View at Publisher · View at Google Scholar · View at Scopus
  61. H. Kawata, T. Kamiakito, Y. Omoto, C. Miyazaki, Y. Hozumi, and A. Tanaka, “RhoC upregulation is correlated with reduced E-cadherin in human breast cancer specimens after chemotherapy and in human breast cancer MCF-7 cells,” Hormones and Cancer, vol. 5, no. 6, pp. 414–423, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. W.-F. Gou, Y. Zhao, H. Lu et al., “The role of RhoC in epithelial-to-mesenchymal transition of ovarian carcinoma cells,” BMC Cancer, vol. 14, no. 1, article 477, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. K. Zins, S. Gunawardhana, T. Lucas, D. Abraham, and S. Aharinejad, “Targeting Cdc42 with the small molecule drug AZA197 suppresses primary colon cancer growth and prolongs survival in a preclinical mouse xenograft model by downregulation of PAK1 activity,” Journal of Translational Medicine, vol. 11, article 295, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. R. Sakamori, S. Yu, X. Zhang et al., “CDC42 inhibition suppresses progression of incipient intestinal tumors,” Cancer Research, vol. 74, no. 19, pp. 5480–5492, 2014. View at Publisher · View at Google Scholar · View at Scopus
  65. S. Akunuru, J. Palumbo, Q. J. Zhai, and Y. Zheng, “Rac1 targeting suppresses human non-small cell lung adenocarcinoma cancer stem cell activity,” PLoS ONE, vol. 6, no. 2, Article ID e16951, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. L. E. Romick-Rosendale, E. E. Hoskins, L. M. Privette Vinnedge et al., “Defects in the Fanconi anemia pathway in head and neck cancer cells stimulate tumor cell invasion through DNA-PK and Rac1 signaling,” Clinical Cancer Research, vol. 22, no. 8, pp. 2062–2073, 2016. View at Publisher · View at Google Scholar
  67. S. M. Mense, D. Barrows, C. Hodakoski et al., “PTEN inhibits PREX2-catalyzed activation of RAC1 to restrain tumor cell invasion,” Science Signaling, vol. 8, no. 370, article ra32, 2015. View at Publisher · View at Google Scholar · View at Scopus
  68. T. Kamai, T. Tsujii, K. Arai et al., “Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer,” Clinical Cancer Research, vol. 9, no. 7, pp. 2632–2641, 2003. View at Google Scholar · View at Scopus
  69. T. Tanaka, D. Nishimura, R.-C. Wu et al., “Nuclear Rho kinase, ROCK2, targets p300 acetyltransferase,” Journal of Biological Chemistry, vol. 281, no. 22, pp. 15320–15329, 2006. View at Publisher · View at Google Scholar · View at Scopus
  70. Z. Ma, M. Kanai, K. Kawamura, K. Kaibuchi, K. Ye, and K. Fukasawa, “Interaction between ROCK II and nucleophosmin/B23 in the regulation of centrosome duplication,” Molecular and Cellular Biology, vol. 26, no. 23, pp. 9016–9034, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. H.-F. Wang, K. Takenaka, A. Nakanishi, and Y. Miki, “BRCA2 and nucleophosmin coregulate centrosome amplification and form a complex with the Rho effector kinase ROCK2,” Cancer Research, vol. 71, no. 1, pp. 68–77, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. Y. An and W. M. Ongkeko, “ABCG2: the key to chemoresistance in cancer stem cells?” Expert Opinion on Drug Metabolism and Toxicology, vol. 5, no. 12, pp. 1529–1542, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. I. L. Beales, A. Hensley, and Y. Loke, “Reduced esophageal cancer incidence in statin users, particularly with cyclo-oxygenase inhibition,” The World Journal of Gastrointestinal Pharmacology and Therapeutics, vol. 4, no. 3, pp. 69–79, 2013. View at Google Scholar
  74. B. Bockorny and C. A. Dasanu, “HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence?” Annals of Hematology, vol. 94, no. 1, pp. 1–12, 2015. View at Publisher · View at Google Scholar · View at Scopus
  75. L. I. de Llobet, M. Baro, R. Mesia, and J. Balart, “Simvastatin enhances the effects of radiotherapy and cetuximab on a cell line (FaDu) derived from a squamous cell carcinoma of head and neck,” Translational Oncology, vol. 7, no. 4, pp. 513–522, 2014. View at Publisher · View at Google Scholar · View at Scopus
  76. S. Moonindranath and H. Shen, “Statins and breast cancer: an overview of the current situation,” Advances in Breast Cancer Research, vol. 5, no. 1, pp. 14–29, 2016. View at Publisher · View at Google Scholar
  77. G. Fritz, C. Henninger, and J. Huelsenbeck, “Potential use of HMG-CoA reductase inhibitors (statins) as radioprotective agents,” British Medical Bulletin, vol. 97, no. 1, pp. 17–26, 2011. View at Publisher · View at Google Scholar · View at Scopus